Author

B. Anghan

Observed names: Anghan, B., B. G. Anghan, Bhavesh Anghan

Observed institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Inserm, Institut Gustave Roussy, Royal Marsden Hospital, Institut Curie

OpenAlex ID: A5013239285

Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?

2011 · Sophie Postel-Vinay, Carlos Gomez-Roca, et al. · Journal of Clinical Oncology · 139

Phase I trials of novel molecularly targeted therapies: Should we pay more attention to toxicities occurring after cycle 1?

2010 · S. Postel-Vinay, C. A. Gomez-Roca, et al. · Journal of Clinical Oncology · 4

Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit.

2011 · J. E. Ang, D. Olmos, et al. · Journal of Clinical Oncology · 3

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

2012 · B. Basu, J. Vitfell-Pedersen, et al. · Oncology · 1

Front & Back Matter

2012 · S.B. Kaye, L.R. Molife, et al. · Oncology

Development, formulation and optimization of polymer based films as potential buccal delivery systems using paracetamol and ibuprofen as model drugs

2010 · Desai, H., Anghan, B. · Greenwich Academic Literature Archive (University of Greenwich)

Works count: 6

Citation count: 147

H-index: 3

I10-index: 1